Clinics in Dermatology
Volume 24, Issue 4 , Pages 260-265 , July 2006

Cushing's syndrome

References 

  1. Cizza G, Nieman LK, Doppman JL, et al. Factitious Cushing syndrome. J Clin Endocrinol Metab. 1996;81:3573–3577
  2. Carpenter PC. Diagnostic evaluation of Cushing's syndrome. Endocrinol Metab Clin North Am. 1988;17:445–472
  3. Simard M. The biochemical investigation of Cushing syndrome. Neurosurg Focus. 2004;16:E4
  4. Atkinson AB, Kennedy AL, Carson DJ, et al. Five cases of cyclical Cushing's syndrome. BMJ. 1985;291:1453–1457
  5. Axelrod L. Glucocorticoid therapy. Medicine (Baltimore). 1976;55:39–65
  6. Trahan AP, Ahemd AR. Corticosteroids: a review with emphasis on complications of prolonged systemic therapy. Ann Allergy. 1989;62:375–390
  7. Oikerinen A, Autio P. New aspects of the mechanism of corticosteroid-induced dermal atrophy. Clin Exp Dermatol. 1991;16:416–419
  8. Sowers JR, Lippman HR, Cushing's syndrome due to ectopic ACTH production: cutaneous manifestations. Cutis 1985;36:351-2, 354.
  9. Stratakis CA, Mastorakos G, Mitsiades CS, et al. Skin manifestations of Cushing disease in children and adolescents before and after the resolution of hypercortisolemia. Ped Dermatol. 1998;15:253–258
  10. Arnaldi G, Angeli A, Atkinson AB, et al. Diagnosis and complications of Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab. 2003;88:5593–5602
  11. Oikarinen AI, Uitto J, Oikarinen J. Glucocorticoid action on connective tissue: from molecular mechanisms to clinical practice. Med Biol. 1986;64:221–230
  12. Zhang W, Watson CE, Liu C, et al. Glucocorticoids induce a near-total suppression of hyaluronan synthase mRNA in dermal fibroblasts and in osteoclasts: a molecular mechanism contributing to organ atrophy. Biochem J. 2000;349:91–97
  13. Lehmann P, Zheng P, Lavker RM, et al. Corticosteroid atrophy in human skin. A study by light, scanning and transmission electron microscopy. J Invest Dematol. 1983;81:169–176
  14. Ross EJ, Linch DC. Cushing's syndrome-killing disease: discriminatory value of signs and symptoms aiding early diagnosis. Lancet. 1982;2:646–649
  15. Mountjoy KG. The human melanocyte stimulating hormone receptor has evolved to become “super-sensitive” to melanocortin peptides. Mol Cell Endocrinol. 1994;102:R7–R11
  16. Callen J. Dermatologic signs of systemic disease. In:  Bolognia JL,  Jorizzo JL,  Rapini RP editor. Dermatology. New York: Mosby; 2003;p. 718–719
  17. Elewski B. Opportunistic mycosis. In:  Elewski B,  Radentz W,  Guptka NK editor. Cutaneous fungal infections. Malden (MA): Blackwell Science; 1998;p. 225–237
  18. Litvin Y, Weinrauch L, Rubinstein N. Reversible, Cushing-induced generalized fungal skin infection. Cutis 1982:30;643, 666, 670.
  19. Nieman LK. Diagnostic tests for Cushing's syndrome. Ann N Y Acad Sci. 2002;970:112–118
  20. Reitmeyer M, Vance ML, Laws ER. The neurosurgical management of Cushing's disease. Mol Cell Endocrinol. 2002;197:73–79
  21. De P, Evans LM, Scanlon MF, et al. “Osler's phenomenon”: misdiagnosing Cushing's syndrome. Postgrad Med J. 2003;79:594–596
  22. Panzer SW, Patrinely JR, Wilson HK. Exophthalmos and iatrogenic Cushing's syndrome. Ophthal Plast Reconstr Surg. 1994;10:278–282
  23. Ferrando AA, Stuart CA, Sheffield-Moore M, et al. Inactivity amplifies the catabolic response of skeletal muscle to cortisol. J Clin Endocrinol Metab. 1999;84:3515–3521
  24. Minetto M, Reimondo G, Osella G, et al. Bone loss is more severe in primary adrenal than in pituitary-dependent Cushing's syndrome. Osteoporos Int. 2004;15:855–861
  25. Lukert BP, Raisz LG. Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med. 1990;112:352–364
  26. Manning PJ, Evans MC, Reid IR. Normal bone mineral density following cure of Cushing's syndrome. Clin Endocrinol (Oxf). 1992;36:229–234
  27. Koch CA, Tsigos C, Patronas NJ, et al. Cushing's disease presenting with avascular necrosis of the hip: an orthopedic emergency. J Clin Endocrinol Metab. 1999;84:3010–3012
  28. Born J, Spath-Schwalbe E, Schwakenhofer H, et al. Influences of corticotropin-releasing hormone, adrenocorticotropin, and cortisol on sleep in normal man. J Clin Endocrinol Metab. 1989;68:904–911
  29. Dorn LD, Burgess ES, Dubbert B, et al. Psychopathology in patients with endogenous Cushing's syndrome: “atypical” or melancholic features. Clin Endocrinol (Oxf). 1995;43:433–442
  30. Sonino N, Fava GA. Psychiatric disorders associated with Cushing's syndrome. Epidemiology, pathophysiology and treatment. CNS Drugs. 2001;15:361–373
  31. Brown ES, Chandler PA. Mood and cognitive changes during systemic corticosteroid therapy. Prim Care Companion J Clin Psychiat. 2001;3:17–21
  32. Heald AH, Ghosh S, Bray S, et al. Long-term negative impact on quality of life in patients with successfully treated Cushing's disease. Clin Endocrinol (Oxf). 2004;61:458–465
  33. Lado-Abeal J, Rodriguez-Arnao J, Newell-Price JD, et al. Menstrual abnormalities in women with Cushing's disease are correlated with hypercortisolemia rather than raised circulating androgen levels. J Clin Endocrinol Metab. 1998;83:3083–3088
  34. Chrousos GP, Torpy DJ, Gold PW. Interactions between the hypothalamic-pituitary-adrenal axis and the female reproductive system. Ann Intern Med. 1998;129:229–240
  35. Luton JP, Thieblot P, Valcke JC, et al. Reversible gonadotropin deficiency in male Cushing's disease. J Clin Endocrinol Metab. 1977;45:488–495
  36. Leibowitz G, Tsur A, Chayen SD, et al. Pre-clinical Cushing's syndrome: an unexpected frequent cause of poor glycaemic control in obese diabetic patients. Clin Endocrinol (Oxf). 1996;44:717–722
  37. Saruta T, Suzuki H, Handa M, et al. Multiple factors contribute to the pathogenesis of hypertension in Cushing's syndrome. J Clin Endocrinol Metab. 1986;62:275–579
  38. Ulick S, Wang JZ, Blumenfeld JD, et al. Cortisol inactivation overload: a mechanism of mineralocorticoid hypertension in the ectopic adrenocorticotropin syndrome. J Clin Endocrinol Metab. 1992;74:963–967
  39. Torpy DJ, Mullen N, Ilias I, et al. Association of hypertension and hypokalemia with Cushing's syndrome caused by ectopic ACTH secretion. Ann N Y Acad Sci. 2002;970:134–144
  40. Mancini T, Kola B, Mantero F, et al. High cardiovascular risk in patients with Cushing's syndrome according to 1999 WHO/ISH guidelines. Clin Endocrinol. 2004;61:768–777
  41. Boscaro M, Sonino N, Scarda A, et al. Anticoagulant prophylaxis markedly reduces thromboembolic complications in Cushing's syndrome. J Clin Endocrinol Metab. 2002;87:3662–3666
  42. Graham BS, Tucker WS. Opportunistic infections in endogenous Cushing's syndrome. Ann Intern Med. 1984;101:334–338
  43. Hill AT, Stewart PM, Hughes EA, Mcleod DT. Cushing's disease and tuberculosis. Respir Med. 1998;92:604–605
  44. Raff H, Findling JW. A physiologic approach to diagnosis of the Cushing syndrome. Ann Intern Med. 2003;138:980–991
  45. Blethen SL, Chasalow FI. Overnight dexamethasone suppression test: normal responses and the diagnosis of Cushing's syndrome. Steroids. 1989;54:185–193
  46. Findling JW, Raff H, Aron DC. The low-dose dexamethasone suppression test: a reevaluation in patients with Cushing's syndrome. J Clin Endocrinol Metab. 2004;89:1222–1226
  47. Wood PJ, Barth JH, Freedman DB, et al. Evidence for the low dose dexamethasone suppression test to screen for Cushing's syndrome-recommendations for a protocol for biochemistry laboratories. Ann Clin Biochem. 1997;34:222–229
  48. Papanicolaou DA, Mullen N, Kyrou I, et al. Nighttime salivary cortisol: a useful test for the diagnosis of Cushing's syndrome. J Clin Endocrinol Metab. 2002;87:4515–4521
  49. Morris D, Grossman A. The medical management of Cushing's syndrome. Ann N Y Acad Sci. 2002;970:119–133

PII: S0738-081X(06)00053-8

doi: 10.1016/j.clindermatol.2006.04.012

Clinics in Dermatology
Volume 24, Issue 4 , Pages 260-265 , July 2006

Article Tools

* Image Usage & Resolution